The first paper to be accepted by the AACR’s latest journal, Blood Cancer Discovery, was published online last week. The paper, which is freely available on the journal website, describes the landscape of mutations present in pediatric acute lymphoblastic leukemia (ALL) and how this landscape changes during treatment, leading to relapse.Read More
The new year began with the good news that death rates from cancer are continuing their steady decline.
A study released this week by the American Cancer Society showed that from …
Around 400 BC, the Greek physician Hippocrates is believed to have first described tumors as “cancer,” using the words “karkinos” or “karkinoma,” which stem from the Greek word for “crab”. Today, hundreds of different types of cancer have been described. As our understanding of this group of diseases continues to grow, cancer prevention, detection, and treatment advancements continue to evolve.Read More
As the year winds down, here’s our final edition of Editors’ Picks for 2019. This regular feature highlights one “must read” article from each journal issue published by the AACR in a given month. This December, articles include results from three clinical trials, an evaluation of a first-in-class FGFR4 inhibitor, and an analysis of breast cancer survival disparities in New Jersey, among others. As always, articles highlighted here are freely available for a limited time.Read More
This infographic explores immunotherapy, cancer treatment that uses the body’s immune system to attack cancer. This timeline illustrates a decade of progress in immunotherapy.Read More
In the past few weeks, the U.S. Food and Drug Administration (FDA) has announced three approvals for new treatments for several types of cancer. On December 18, the FDA approved the new molecularly targeted therapeutic enfortumab vedotin-ejfv (Padcev) to treat certain patients who have bladder cancer; on November 21, the agency expanded the use of the molecularly targeted therapeutic acalabrutinib (Calquence) to include treating adults who have chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL); and on November 14, it approved the new molecularly targeted therapeutic zanubrutinib (Brukinsa) to treat certain patients who have mantle cell lymphoma.Read More
Each month, the editors from the portfolio of scientific journals published by the American Association for Cancer Research (AACR) highlight one “must read” article from every journal issue, which we summarize here. This month’s edition is stuffed with studies relating to recent clinical trials, a preclinical investigation of NSAIDs for the inhibition of colon tumor progression, and many more. As always, articles featured here are freely available for a limited time.Read More
November is National Family Caregivers Month—a time to raise awareness for the approximately 3 million people in the U.S. who act as caregivers to their relatives, friends, or partners—all while juggling other demanding roles in life.
An article appearing in the fall issue of Cancer Today, a resource for cancer patients, survivors, and caregivers, highlights efforts to understand the nature of distress in caregiving and better ways to provide support for those who need it.Read More
Lung cancer – one of the most commonly diagnosed cancers in the United States – is an area of intense research and clinical development. While there has been extraordinary progress …Read More
Earlier this year, the American Association of Cancer Research (AACR) partnered with Novocure, a global oncology company, to launch several new funding initiatives to support innovative research focused on Tumor Treating Fields (TTFields). TTFields is a novel noninvasive cancer therapy approved by the U.S. Food and Drug Administration for the treatment of adults with glioblastoma multiforme (GBM) and malignant pleural mesothelioma (MPM). Patients wear a portable electric field generator that delivers TTFields to tumors via electrodes attached to the skin over the tumor site.Read More